In order to study the role of FASN in the acquisition of EGFR TKI resistance in NSCLC, we used the sensitive PC9 cell line carrying the EGFR exon 19 deletion (ELREA) and three GR models, two T790M+ models (PC9-GR1 and PC9-GR4), and one T790M− model (PC9-GR3) [45]. Here, FASN is linked to non-small cell lung carcinoma.